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Abstract 
The small G protein ADP-ribosylation factor 6 (Arf6) plays pivotal roles in a wide variety of 
cellular events such as endocytosis, exocytosis, and actin cytoskeleton reorganization. 
However, the physiological functions of Arf6 at the whole animal level have not yet been 
thoroughly understood. The purpose of this study is to clarify physiological functions of Arf6 
in lymphatic endothelium in mice. Here, I show that Arf6 regulates developmental and tumor 
lymphangiogenesis in mice. I generated and analyzed lymphatic endothelial cell 
(LEC)-specific Arf6 conditional knockout (LEC-Arf6 cKO) mice, and found that these mouse 
embryos exhibit severe skin edema and impairment in the formation of lymphatic vessel 
network at the mid-gestation stage. Furthermore, I found that knockdown of Arf6 in human 
LECs inhibits in vitro capillary tube formation and directed cell migration induced by 
vascular endothelial growth factor-C (VEGF-C), and Arf6 mediates VEGF-C-induced cell 
migration through the internalization of β1 integrin. Finally, it was found that LEC-Arf6 cKO 
mice transplanted with B16 melanoma cells attenuated tumor lymphangiogenesis and 
progression. Collectively, these results provide evidence that Arf6 in LECs plays a crucial 
role in physiological and pathological lymphangiogenesis. 
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1. Introduction 
1-1. Small GTPase  
Small GTPases or small guanine nucleotide-binding proteins (small G proteins) with 
molecular weight of about 20 kDa are conserved from yeast to human [1]. To date, more than 
100 membranes of small G protein superfamily have been identified, and are classified into 
five families including Ras, Rho, Rab, Ran, and Arf family based on similarity of their 
functions and sequences (Figure 1A). Small G proteins cycle between GDP-bound inactive 
and GTP-bound active forms to regulate a wide variety of cellular functions, such as gene 
expression, cytoskeletal reorganization, vesicle trafficking, nucleocytoplasmic transport, and 
microtubule organization (Figure 1B). In the resting state of the cell, they exist as the 
GDP-bound inactive form. Upon stimulation of the cell by  
 
 
Figure 1. Small G protein superfamily 
(A) Small G protein superfamily. Five families of small G protein including Ras, 
Rho, Rab, Ran, and Arf are categorized based on their functions. (B) Small G 
protein functions as molecular switches in signal transduction pathways by cycling 
between GDP-bound inactive and GTP-bound active states, which are precisely 
regulated by GEFs and GAPs. The activated small G protein transduces signals 
downstream. Thereafter, GTP on small G protein is hydrolyzed to GDP by the 
GTPase activity of small G protein, which is activated by GAPs, to become 
inactive. 
A 
B 
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agonists, such as hormones and growth factors, GDP on small G proteins is replaced for GTP 
to become active, which is accelerated by the guanine nucleotide exchange factors (GEFs). 
Activated small G protein interacts with their downstream effectors to transduce signals by 
regulating the cellular location and activity of effectors. Thereafter, GTP bound to small G 
proteins is hydrolyzed by their GTPase activity. Since the GTPase activities of small G 
proteins are very low, GTPase-activating proteins (GAPs) function to stimulate the GTPase 
activity of small G proteins. Thus, GEFs and GAPs support cycling of small G proteins 
between the inactive and active status for small G proteins to regulate signaling transduction 
and small G proteins function as molecular switches in signal transduction pathways. 
 
1.2. Arf family 
Arf proteins were first identified by Kahn, et al. as cofactors for cholera toxin-catalyzed 
ADP-ribosylation of α-subunit of the heterotrimeric GTP-binding protein Gs, which 
stimulates adenylyl cyclase [2]. At present, Arfs are known to regulate membrane traffic by 
recruiting coat proteins, phospholipid metabolism and reorganization of actin cytoskeleton [3, 
4]. Arf family is composed of Arf proteins, structurally resemble Arf-like proteins (ARLs) 
and Arf-related proteins (ARPs), and the secretion-associated and Ras-related protein (SAR) 
[5]. The mammalian Arf proteins consist of Arf1-6, which are classified into three classes 
based on their sequence homology: Class I includes Arf1, Arf2, Arf3, class II Arf4 and Arf5, 
and class III (Arf6) (Figure 2) [4]. Class I and II of Arfs localize on the endoplasmic 
reticulum and Golgi apparatus. The sole member of class III, Arf6, localizes at the plasma 
membrane and endosomal compartments, such as early endosome and recycling endosome. 
These spatially specific locations of Arfs differentiate their functions in the cell. Class I and II 
of Arfs regulate the assembly of different types of coat protein complexes on budding vesicles 
along the secretory pathway [6] and recruitment of coat components to trans-Golgi 
membranes [7, 8]. On the other hand, Arf6 plays pivotal roles in endosomal membrane 
trafficking and actin cytoskeleton reorganization [4, 9, 10]. 
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Figure 2. Mammalian Arf proteins and their cellular localization 
Arf proteins are composed of 6 isoforms, Arf1-6, which are classified into 3 classes 
based on their sequence homology. Class I and II of Arfs localize to the Golgi 
apparatus and endoplasmic reticulum. Arf6, the sole member of class III, localizes 
at the plasma membrane and endosome. 
 
The structure of Arf6 contains the N-terminal amphipathic helix, the effector-binding 
regions, switch1 (SW1) and SW2, and an interswitch region (Figure 3) [11]. Arf6 is 
post-translationally myristoylated at the N terminus, and this modification is essential for 
membrane binding and biological activity of Arf6 [11]. The myristoyl chain and associated 
N-terminal amphipathic helix are inserted into the membrane when Arf6 is activated [12]. 
SW1 and SW2 regions change their conformations in response to the Arf6 activation and are 
involved in interactions with Arf6 effectors [13]. Therefore, Arf6 effectors are expected to 
localize cellular components where the GTP-bound active form of Arf6 localizes. 
 
 
 
 
Figure 3. Scheme of structure domains of Arf6 
Arf6 contains an amphipathic helix at N-terminal, which is post-translationally 
myristoylated, two effector-binding regions of switch1 (SW1) and SW2, and an 
interswitch region between the two effector-binding regions. 
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1-3. Arf6 GEFs and GAPs 
To date, 14 members of Arf GEFs family, which are classified into exchange factor for Arf6 
(EFA6), cytohesin, brefeldin A-resistant Arf-guanine nucleotide exchange factor (BRAG), 
Golgi-specific brefeldin A-resistant Arf-guanine nucleotide exchange factor 1 (GBF1), and 
brefeldin A-inhibited GEF (BIG) subfamilies, have been identified (Figure 4) [14, 15]. Of 
these Arf GEFs, 8 members have been identified to be specific to Arf6. Their structures 
conserve the Sec7 domain, which is responsible for GEF activity to Arfs. The mammalian 
EFA6 family is composed of four proteins, EFA6A, EFA6B, EFA6C and EFA6D [16], which 
are highly selective for Arf6 [17]. Three BRAGs are BRAG1 (IQSec2), BRAG2 
(IQSec1/GEP100) and BRAG3 (IQSec3/synArf6 GEF) [15], but only BRAG2 is specific for 
Arf6 [18]. Cytohesins are expressed in all vertebrates in four isoforms, cytohesin1, 
cytohesin2/ARNO, cytohesin3/Grp1 and cytohesin4 [15]. 
Arf GAP family so far identified includes 31 members, which are classified into ACAP, 
ARAP, ASAP, GIT, SMAP, ADAP, ArfGAP1, ArfGAP2, AGAP and AGFG subfamilies 
(Figure 4). They conserve the zinc-finger Arf GAP domain, which is responsible for 
stimulating GTPase activity of Arfs. Although the specificity of each member of Arf GAPs to 
Arf isoforms has not yet been fully clarified, in vitro analyses have revealed that at least 9 
members of Arf GAPs are specific to Arf6. 
 
 
 
Figure 4. Arf6 GEF and GAP family members 
To date, 8 members of Arf6 GEFs, which belong to BRAG, cytohesin, and EFA6 
families, and 9 members of Arf6 GAPs, which belong to GIT, ARAP, ACAP, and 
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SMAP families, have been identified. They are shown in red color. 
 
1.4. Arf6 effectors 
Arf6 effectors so far identified, which are classified into three groups, 
phospholipid-metabolizing enzymes, Arf6 GAPs and others, are shown in Figure 5. The 
active form of Arf6 regulates a wide variety of cellular functions through the regulation of 
locations and activities of these effectors. 
 
Figure 5. Effector proteins of Arf6 
Three types of Arf6 effector proteins are described, including 
phospholipid-metabolizing enzymes, Arf6 GAPs, and others.  
 
1-4-1. Phospholipid-metabolizing enzymes 
Arf6 has been shown to activate two lipid-metabolizing enzymes, phospholipase D (PLD) 
(Figure 6) [19, 20] and phosphatidylinositol 4-phosphate 5-kinase (PIP5K) [21, 22]. PLD 
catalyzes the hydrolysis of phosphatidylcholine (PC) to the lipid messenger phosphatidic acid 
(PA), which controls membrane ruffling, endocytosis, exocytosis, stress fibers induction, 
respiratory burst, and Golgi transport (Figure 6) [23]. PIP5K generates the pleiotropic 
phospholipid phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] by phosphorylating 
phosphatidylinositol 4-phosphate (PI4P) at the 5 position of the inositol ring: PI(4,5)P2 
regulates membrane channel activity [24], membrane trafficking [25], Golgi structure and 
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function [26, 27], actin dynamics [28], and nuclear activities (Figure 6) [29]. Interestingly, PA 
functions as a cofactor in the activation of PIP5K by Arf6, and PI(4,5)P2 interacts with and 
activates PLD (Figure 6) [30]. This crosstalk explains these two Arf6 downstream effectors 
share the regulation of the same cellular functions. Thus, Arf6 mediates multiple cellular 
functions through regulating PLD and PIP5K activities. 
 
 
Figure 6. Arf6 activates PLD and PIP5K to regulate a wide variety of cellular 
functions 
Arf6 activates PLD and PIP5K to produce PA and PI(4,5)P2, respectively, to 
regulates cellular functions described in the figure. PA and PI(4,5)P2 support the 
activation of PIP5K and PLD by Arf6, respectively. 
 
1-4-2. Arf6 GAPs 
Arf6 GAPs are listed in Figures 4 and 5. In addition to the function of Arf6 GAPs to support 
the hydrolysis of GDP on Arf6 by stimulating the GTPase activity of Arf6, Arf6 GAPs seem 
to function as a recruiter of signaling molecules (Figure 7) [31-34]. For instance, ACAP1 is 
involved in β1 integrin recycling by associating endosomal β1 integrin [35]. Moreover, 
SMAP1 has been reported to participate in the clathrin-dependent and constitutive 
endocytosis of transferrin receptor (TfnR) [31]: Arf6-bound SMAP1 recruits clathrin and the 
adaptor protein complex-2 (AP-2) to the plasma membrane, thereby stimulating endocytosis 
of TfnR. Additionally, ASAP1 interacts with cortactin and paxillin to form a trimeric protein 
complex, which is critical for the formation of invadopodia [36]. In this sense, Arf6 GAPs 
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function as effector proteins of Arf6 in a wide variety of signaling pathways. 
 
 
Figure 7. Arf6 effectors including Arf6 GAPs and other signaling molecules 
Arf6 regulates cellular functions through a wide variety of effectors, such as Arf6 
GAPs, lipid-metabolizing enzymes, and other effectors, to regulate membrane 
traffic of receptors, cadherins, and integrins. The cellular signaling through these 
effectors control cell motility, and membrane ruffle formation by reorganization 
of the actin cytoskeleton. 
 
1-4-3. Other Arf6 effector proteins 
In addition to the phospholipid-metabolizing enzymes and GAPs, other proteins also function 
as downstream effectors for Arf6 to regulate cellular functions (Figure 7). For example, 
monomeric clathrin adaptors β-arrestin1/2 that bind clathrin and PI(4,5)P2 to recruit cargo and 
promote clathrin-dependent endocytosis functions as an Arf6 effector [37]. The nucleoside 
diphosphate (NDP) kinase Nm23-H1 is recruited to the cell-cell contact region and provides a 
source of GTP during dynamin-dependent vesicle fission in an Arf6-dependent manner [38, 
39]. The secretory carrier membrane protein, SCAMP2, functions in setting up the soluble 
NSF attachment protein (SNAP) receptor (SNARE) interactions with the secretory vesicle 
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and plasma membranes, and facilitates fusion pore formation in the SNARE-mediated fusion 
of the vesicle exocytosis [40]. The c-Jun-N-terminal-kinase interacting protein 3 (JIP3) and 
JIP4 interact with kinesin-1 and dynactin complex to control the trafficking of recycling 
endosomes during cytokinesis in an Arf6-dependent manner [41]. Sec10, the subunit of the 
exocyst complex, is involved in docking of vesicles with the plasma membrane and regulates 
the post-endocytic recycling downstream of Arf6 [42, 43]. The dual Rab11/Arf6 binding 
proteins, FIP3/Arfophilin-1 and FIP4/Arfophilin-2, regulates cytokinesis through coupling 
with Rab11-positive vesicle traffic from recycling endosomes to the cleavage furrow [44]. 
Arfaptin-2, to which Arf6 binds to, is known as the partner of Rac1 and regulates cytoskeletal 
rearrangements at the cell periphery [45]. The Rac1 GEF Dock180 and Kalirin were both 
indicated to mediate cytoskeletal and focal adhesion regulation through control the activity of 
Rac1 downstream of Arf6 [46]. Tre-2/Bub2/Cdc16 (TBC) domain-containing protein TRE17 
regulates plasma membrane-endosome trafficking via promoting the localization of Arf6 to 
the plasma membrane and Arf6 activation [47]. Thus, these molecules are believed to be Arf6 
effectors. 
 
 
1-5. Cellular functions of Arf6 
1-5-1. Endocytosis 
Arf6 mediates clathrin-dependent endocytosis of membrane proteins, such as TfnR [9], 
β2-adrenergic receptor [48], E-cadherin [49] and G-protein-coupled receptors (GPCRs) 
(Figure 7) [50]. The initial step of endocytosis of cell membrane proteins is the translocation 
of the active form of Arf6 from the cytosol to the plasma membrane. In the clathrin-mediated 
endocytosis, the active form of Arf6 binds to and activates PIP5K to produce PI(4,5)P2 [21], 
which regulates clathrin-mediated endocytosis [51] via the recruitment of AP-2 and clathrin 
on coated pits formed at the plasma membrane [22, 52]. Thereafter, Arf6 GAPs trigger the 
budding of vesicles from the plasma membrane by inactivating Arf6 [31]. Interestingly, 
vesicle formation and budding from the plasma membrane are determined by a cargo protein. 
For example, the Arf6 GAP SMAP1 functions in the endocytosis of TfnR [53]. GIT1 plays a 
role in the interleukin (IL)-mediated endocytosis of GPCRs and epidermal growth factor 
receptors (EGFRs) [50]. Thus, the GTP/GDP cycling of Arf6 coordinates the recruitment of 
AP-2 and clathrin to activated receptors during the endocytic process [54]. 
Arf6 also regulates the clathrin-independent endocytosis (CIE) pathway (Figure 7). The 
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cargo proteins include the major histocompatibility complex class I protein (MHC class I), 
M2-muscarinic acetylcholine receptors, and the peripheral myelin-membrane protein [4]. 
Cargos through Arf6-associated CIE are sorted to recycling or degradation pathway based on 
specific cytoplasmic sequences [55, 56] and ubiquitination of the cytoplasmic tails of these 
cargo proteins [57]. However, the detailed mechanism of the CIE pathway is still unclear and 
requires more investigation. 
 
1-5-2. Cell adhesion 
In epithelial cells, Arf6 modulates the cell-cell contact through recruiting Nm23-H1 for 
facilitating dynamin-dependent endocytosis of E-cadherin (Figure 7) [39]. This endocytosis of 
E-cadherin leads the disassembly of adherens junctions, thereby regulating epithelial cell 
scattering and the epithelial-mesenchymal transition (EMT) of cancer cells. Arf6 also 
regulates the contact of cell-extracellular matrix (ECM) via trafficking of β1 integrin and 
syndecan-2 (Figure 7) [58-60]. 
 
1-5-3. Invadopodia formation and microvesicle releasing 
It has been reported that Arf6 is involved in cancer invasion and GTP/GDP cycle of Arf6 is 
critical for the invasion of melanoma, glioma, and breast cancer cells (Figure 7) [4, 55, 61-63]. 
Moreover, Arf6 has been implicated in the regulation of invadopodia formation/turnover [4] 
and protease secretion to degrade ECM [62]. Invadopodia are actin-rich membrane 
protrusions with integrins and associated signaling proteins. In order to form the invadopodia, 
Arf6 recruits the Arf6 GAP ASAP1 to link paxillin and cortactin in malignant breast cancer 
cells [34]. For the protease release from tumor cells to degrade ECM, Arf6 modulates the 
shedding of plasma membrane-derived microvesicles with protease cargo into the surrounding 
environment through phospholipid metabolism and the activation of extracellular 
signal-regulated kinase (ERK) [62]. 
 
1-5-4. Exocytosis 
Arf6 has been implicated in the regulation of protein secretion (Figure 7). For instance, the 
secretion of adipsin from adipocytes [64], neurotransmitters and human growth hormones by 
Ca2+-dependent dense-core vesicle (DCV) exocytosis from PC12 cells [65, 66], and insulin 
from pancreatic β cells [67]. SCAMP2 interacts with PLD1, Arf6, and ARNO, and this 
association is crucial for the SNARE-mediated fusion of vesicles with the plasma membrane 
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for exocytosis [40]. Arf6-mediated exocytic pathway also requires activation of PIP5K by 
Arf6 to increase PI(4,5)P2 level on the plasma membrane [67]. 
 
1-5-5. Membrane ruffle formation 
Membrane ruffle formation requires activation of peripheral PIP5K through Arf6 to produce 
PI(4,5)P2 (Figure 7) [21], which induces reorganization of actin cytoskeleton. In addition, 
Arf6 effectors, the Rac1 GEF Dock180 and Kalirin, activate Rac1 [68, 69], leading to the 
rearrangement of actin cytoskeleton in the signaling pathway for membrane ruffle formation. 
 
1-5-6. Phagocytosis 
During phagocytosis, membranes are delivered from internal stores to particle internalization 
sites of the plasma membrane to accommodate pseudopod extension and ingest particles. Arf6 
is involved in Fc receptor (FcR)-regulated phagocytosis, which is thought to require actin 
cytoskeleton reorganization (Figure 7) [70-73] and occur through the activation of the Rac1 
and lipid metabolism [74]. 
 
1-5-7. Macropinocytosis 
Macropinocytosis is the process to engulf the large volumes of fluid by extension, folding and 
closure of the plasma membranes [75]. To drive internalization, the actin filaments generate 
forces by modulating dynamics of actin assembly [76, 77], which form the dorsal ruffles. It 
has been shown that the Arf6 effector domain-containing proteins regulate membrane 
trafficking (Figure 7) [78]. The primate-specific TBC1D3 regulates EGF-mediated 
macropinocytosis in an Arf6-dependent manner [79]. In addition, TBC1D3 interacts and 
coordinates with Golgi-localized, gamma adaptin ear-containing, Arf-binding protein 3 
(GGA3) to facilitate the macropinocytotic process. Interestingly, TBC1D3 lacks the arginine 
residue that is responsible for the Rab-GAP activity, but there is no clear evidence of its 
Arf6-GAP activity. Interestingly, another TBC protein TRE17 has been shown to bind to the 
GDP-form of Arf6 and activate Arf6 for regulation of the plasma membrane-endosome 
trafficking via cooperating with Arf6 GEFs [47]. 
 
1-5-8. Proliferation 
Arf6 has been indicated to regulate cell proliferation and mitosis (Figure 7) [80-82]. Arf6 
induces cell proliferation through activating PLD and S6K1 kinase in a 
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PLD-mTORC1-dependent manner, thereby contributing to mitosis [83]. In addition, P38 
MAPK accelerates the Arf6-mediated cell proliferation. It has been revealed that 
EGF-induced Arf6 expression plays an important role in the proliferation of glioma cells [84]. 
Arf6 also regulates hedgehog (Hh) signaling through cooperating with EGFR to induce Ras 
tumor growth [85]. Arf6 activates TRE17 to promote cell proliferation [86]. Arf6 activation 
induces the trafficking of β-catenin and guanine nucleotide-binding protein G(q) subunit α 
(GNAQ) from the plasma membrane to the nucleus and cytoplasmic vesicles, receptively [87]. 
Thereafter, multiple signaling pathways through Rho/Rac, YAP, and PLC/PKC are activated, 
which are involved in the proliferation of melanoma cells. 
 
1-6. Physiological functions of Arf6 
Although the functions of Arf6 at the cellular level have been well studied, the physiological 
significance of Arf6 remain unclear. To address this issue, the laboratory to which I belong 
had generated Arf6 knockout (Arf6-/-) mice, and analyzed them. Kanaho and his colleagues 
have reported that Arf6-/- mice are embryonic lethal at midgestation with defect in the liver 
development [88]. Moreover, they have generated several tissue- and cell type-specific 
conditional knockout (cKO) mice, and found that endothelial-specific Arf6 cKO mice show 
the defect in tumor angiogenesis [60] and that keratinocyte-specific Arf6 cKO mice show a 
significant delay in the wound healing of the skin [89]. Neuron-specific Arf6 cKO mice 
display the defect in the oligodendrocyte myelination in the hippocampal fimbria and the 
corpus callosum [90]. Platelet-specific Arf6 cKO mice show the defect in platelet spreading 
and blood clot by causing the aberrant αIIbβ3 integrin trafficking [91]. 
 
1-7. Lymphangiogenesis 
The lymphatic system is comprised of a blind-ended network of lymphatic vessels, which 
collect and transport the interstitial fluid and lymph, and plays critical roles in homeostasis of 
tissue fluid, lipid absorption, and immune surveillance. Malfunction of lymphatic vessels is 
pivotal and associate with a wide variety of diseases such as inflammation, fibrosis, 
metastasis, and lymphedema [92]. Development of lymphatic vasculature in the embryo 
initiates from a subset of venous endothelial cells that follow by the specification of lymphatic 
endothelial cell fate, sprouting, morphogenesis, and network formation (Figure 8). Venous 
endothelial cells expressing the lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the 
central veins serve as lymphatic endothelial cell (LEC) precursors, which express the 
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transcription factor SRY-box 18 (Sox18) to express the key transcription factor 
prospero-related homeobox gene 1 (Prox1), the marker for LECs, in mice at approximately 
embryonic day (E) 9.5 [93]. Prox1-expressing LECs in the cardinal vein assemble the 
pre-lymphatic clusters, migrate away from the cardinal vein wall to form the lymph sacs and 
superficial lymphatic vessels at E10.5-13.5 [93-96]. The sprouting of lymphatic vessels from 
the lymph sac is induced by VEGF-C through its receptor VEGFR3 [97], which regulates 
receptor modulators such as Neuropilin 2 (Nrp2) [98], Ephrin B2 [99] and β1 integrin 
[100-102] to generate the lymphatic vascular network in mouse embryos within E14.5. In 
addition, LECs express the membrane glycoprotein podoplanin [103, 104], which activates 
the Syk tyrosine kinase through C-type lectin receptor 2 (CLEC-2) in platelets [105, 106]. 
This activation leads to platelet aggregation [106, 107]. From E15.5 to postnatal stage, the 
primary lymphatic networks undergo remodeling to form a mature lymphatic network 
composed of initial lymphatic vessels, pre-collectors and collecting lymphatic vessels [108]. 
Finally, these lymphatic network forms intraluminal valves, recruits smooth muscle cells, 
develop continuous inter-endothelial junctions, and produce a basement membrane [92]. 
 
 
Figure 8. Lymphangiogenesis during mouse embryonic development 
During embryonic lymphatic vessel development, a subset of LECs in cardinal vein 
expresse Prox1, and migrate out to form the lymph sac. Thereafter, lymphatic 
vessels are formed and then initiate outgrowth in response to VEGF-C to construct 
the lymphatic network. Various markers are identified and specifically expressed in 
developing cells. 
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1-8. Tumor lymphangiogenesis 
It has been known that cancer cells disseminate or metastasize to distal organs via either 
angiogenesis or lymphangiogenesis (Figure 9). Since the lymphatic vessels are single thin 
layers and have larger diameters than blood vessels [92], cancer cells easily invade into the 
lymphatic system. More evidence revealed that the density of lymphatic vessels correlates 
with the incidence of lymph node metastasis and poor prognosis in some human cancers [109, 
110], indicating that tumor lymphangiogenesis is a pivotal process for cancer progression and 
metastasis. Tumor lymphangiogenesis is mediated by lymphangiogenic factors, VEGF-C and 
VEGF-D, that are produced by tumors, stromal cells, macrophages, and activated platelets 
[111-114]. These factors stimulate growth and dilation of the peritumoral lymphatic vessels, 
thereby enhancing tumor cell invasion into lymphatic vessels and lymph node, and facilitating 
dissemination of tumor cells to distal organs [109, 115-117]. Therefore, blockage of 
lymphangiogenic factors has been implied in the suppression of metastasis: blockage of 
VEGFR3 signaling in mice significantly reduces tumor lymphangiogenesis and lymphatic 
metastasis [118-121]. Inhibition of neuropilin-2 inhibits lymphatic endothelial cell migration, 
resulting in the suppression of tumor lymphangiogenesis and metastasis to sentinel lymph 
nodes [122]. 
 
 
Figure 9. Tumor lymphangiogenesis 
In tumor environment, not only tumor cells but also inflammatory cells and 
stromal cells secret various lymphatic growth factors. These factors stimulate 
tumor lymphangiogenesis, which facilitates the invasion of cancer cells into the 
lymphatic system. 
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1-9. Lymphatic disorder 
Several lymphatic genes have been identified by lineage-tracing studies in mice to validate 
the development of lymphatic vessel and association with human lymphatic disorders. For 
example, the VEGFR3 mutation causes Milroy disease [123], and mutation in its ligand 
VEGF-C is associated with autosomal dominant Milroy-like lymphedema [124]. 
Hypotrichosis-lymphedema-telangiectasia patients have a mutation in transcription factor 
SOX18, which has been identified to induce Prox1 expression in venous LEC progenitors 
[125, 126]. Collagen and calcium binding EGF domains 1 (CCBE1) mutations cause lymph 
vessel dysplasia that associate with Hennekam syndrome [127, 128]. Mutation of Forkhead 
box protein C2 (FOXC2), which regulates lymphatic valves formation and lymphatic 
remodeling, was found in lymphedema-distichiasis syndrome [129]. 
Although various guidance molecules, cellular interactions, and extrinsic forces are 
involved in embryonic lymphangiogenesis [130], the molecular mechanisms for lymphatic 
vascular network formation are poorly understood and require more research to elucidate it.  
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2. Aim 
Since the small G protein Arf6 plays pivotal roles in a wide variety of cellular events, such as 
endocytosis, exocytosis, and actin cytoskeleton reorganization [14, 21], the physiological 
functions of Arf6 at the whole animal level have not been well elucidated. In the previous 
study, it has been demonstrated that Arf6-/- mice are embryonic lethal at midgestation with 
liver development defect [88]. Here, I aim to re-examine the different stages of Arf6-/- 
embryos in depth and clarify the cause of edema in Arf6-/- embryos. In addition, I aim to 
elucidate the physiological and pathological functions of Arf6 in LECs by generating 
LEC-specific Arf6 cKO mice and analyzing them.  
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3. Materials and methods 
Mice 
Arf6-/- and Arf6flox/flox mice were generated as described previously [60, 88, 90]. LEC-Arf6 
cKO mice were generated by mating Arf6flox/flox and Prox1-CreERT2 mice, which were kindly 
provided by Dr. S. Ito (Showa Pharmaceutical University, Japan) [94]. To initiate 
Cre-mediated recombination in embryos, pregnant mice were intraperitoneally injected with 3 
mg of tamoxifen  dissolved in sunflower oil every day from E10.5 [94]. 
ROSA26-CAGp-loxP-EGFP-loxP-tdsRed (R26GRR) mice provided by Dr. S. Takahashi 
(University of Tsukuba, Japan) were used to validate the Cre activity in LECs [131, 132]. All 
experiments using mice were performed according to the Guidelines for Proper Conduct of 
Animal Experiments, Science Council of Japan, and the protocols were approved by the 
Animal Care and Use Committee of University of Tsukuba. 
 
Whole-mount immunofluorescence staining of embryonic dorsal skin 
After mouse embryos were fixed with 4% paraformaldehyde (PFA)/PBS at 4°C and 
subsequently dehydrated in methanol, the dorsal skin was dissected, rehydrated in PBST 
(0.2% Tween-20/PBS), and incubated in the blocking buffer consisting of 0.1 M Tris-HCl, 
pH7.5, 0.5% blocking reagent (PerkinElmer Life Sciences) and 0.15 M NaCl for 1 hr at room 
temperature (r.t.). The skin samples were incubated with the primary antibodies against 
LYVE-1 (Abcam), Prox1 (R&D Systems), PECAM-1 (BD Biosciences), or Ki67 (Abcam) at 
4°C overnight and subsequently with Alexa Fluor®-488-, Alexa Fluor®-546-, Alexa 
Fluor®-594-, Cy3-, and Cy5-conjugated secondary antibodies (Thermo Fisher Scientific). 
Immunofluorescence images were obtained with Biozero BZ-X700 microscope (Keyence, 
Japan) or Leica TCS SP5 confocal microscope. The branch number, total vessel length, and 
width of lymphatic vessels were analyzed by NIH ImageJ software. 
 
Tissue sections and immunohistochemical analysis 
Embryos were fixed with 4% PFA/PBS at 4°C overnight, equilibrated in 30% sucrose/PBS, 
then embedded in OCT compound. Embedded embryos were cryosectioned at 14-16 µm, and 
subjected to immunohistochemical analysis. For the immunohistochemical analysis, sections 
were washed with PBS, and blocked with the blocking buffer at r.t. for 1 hr. Sections were 
then incubated with anti-Arf6, which was kindly provided by Dr. H. Sakagami (Kitasato 
University, Japan), anti-LYVE-1, anti-Prox1, or anti-PECAM-1 antibody at 4°C overnight. 
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After washing with PBST, sections were incubated with Alexa Fluor®-488 goat 
anti-rabbit IgG antibody at r.t. for 1 hr, and counterstained with DAPI. Images were 
obtained with Biozero BZ-X700 microscope. 
 
Isolation of primary mLECs and mVECs 
Skins dissected from E16.5 embryos were digested with the solution consisting or 1 mg/ml of 
deoxyribonuclease I, 2.5 mg/ml of collagenase type II and type IV, 20% FBS, and 10 mM 
HEPES buffer in DMEM. Macrophages and hematopoietic cells were removed by incubating 
the cell suspension with rat anti-F4/80 (MCA497GA, Bio-Rad) and -CD45 antibody 
(B122583, BioLegend) and subsequently precipitating with goat anti-rat IgG microbeads 
(Miltenyi Biotec). Mouse LECs (mLECs) and mouse VECs (mVECs) in the cell suspension 
were captured by rabbit anti-LYVE-1 (ab14917, Abcam,) and rat anti-PECAM-1 antibody 
(102501, BioLegend), and precipitated with goat anti-rabbit IgG microbeads (Miltenyi 
Biotec). Captured mLECs and mVECs were sorted using The MiniMACSTM kit (Miltenyi 
Biotec) as described previously.[133] Isolated mLECs and mVECs were immediately used for 
detection of mRNAs and proteins. 
 
Reverse transcription and quantitative real-time PCR 
Total cellular RNA was extracted from the cells using the TRIzol® Reagent (Life 
Technologies, Carlsbad, CA). The reverse transcription of the RNA (1.5 µg) was performed in 
a 30 µl reaction mixture using SuperScriptTM III Reverse Transcriptase (Thermo Fisher 
Scientific) and oligo-dT primers. Quantitative real-time PCR (qRT-PCR) reactions were 
conducted in Applied Biosystems 7500/7500 Fast Real-Time PCR System (Thermo Fisher 
Scientific) using THUNDERBIRDTM SYBR® qPCR Mix (TOYOBO) according to 
manufactory’s instruction. The thermal profile of PCR was at 95°C for 3 min, followed by 40 
cycles at 95°C for 30 sec and 60°C for 30 sec. The sequences of paired primers for qRT-PCR 
are as follows: 
Actin beta (Actb) forward: 5’-GATCATTGCTCCTCCTGAGC-3’ 
Actb reverse: 5’-GTCATAGTCCGCCTAGAAGCAT-3’ 
Prox1 forward: 5’-CTGGGCCAATTATCACCAGT-3’ 
Prox1 reverse: 5’-GCCATCTTCAAAAGCTCGTC-3’ 
Lyve1 forward: 5’-TGGTGTTACTCCTCGCCTCT-3’ 
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Lyve1 reverse: 5’-TTCTGCGCTGACTCTACCTG-3’ 
Flt1 forward: 5’-AGCACCTTGACCTTGGACAC-3’ 
Flt1 reverse: 5’-CAGGGGATGATGAGCTGTCT-3’ 
Arf6 forward: 5’-TGCCTAAACTGGAGGAAACTTGAA-3’ 
Arf6 reverse: 5’-ACCACATCTCACCTGCAACATT-3’ 
GAPDH forward: 5’-AAGGTGAAGGTCGGAGTC-3’ 
GAPDH reverse: 5’-TGTAGTTGAGGTCAATGAAGG-3’ 
 
Cell culture and siRNA transfection 
Human LECs (hLECs; Lonza) were cultured in EGMTM-2 MV Medium (Lonza) and 
maintained within 5 passages. siRNAs for Arf6 (Dharmacon) were transfected with 
Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instruction. 
B16 melanoma cells were maintained in Dulbecco’s modified Eagle medium (DMEM; 
Nacalai Tesque, Japan) supplemented with 10% fetal bovine serum, penicillin, and 
streptomycin. 
 
Cell proliferation assay 
For the cell proliferation assay, siRNA-transfected hLECs were cultured in EGMTM-2 MV 
Medium on 35-mm dishes for two days and harvested by Accutase treatment (Nacalai 
Tesque), and the cell number was counted. 
 
In vitro capillary tube formation by hLECs 
hLECs cultured on 24-well plates coated with the growth factor-reduced Matrigel (BD 
Biosciences) at 1.5 × 105 cells per well were starved, transfected with siRNAs for Arf6, and 
stimulated with 200 ng/ml of VEGF-C (R&D Systems). After 12 hr of the stimulation, cell 
images were obtained using the Biozero BZ-X700 microscope, and the capillary tube length 
was measured by NIH ImageJ software. 
 
Assays for wound healing and cell migration 
For the wound healing assay, hLECs transfected with siRNA for Arf6 were grown on 24-well 
plates to full confluency and starved in serum-free EBMTM-2 Basal Medium (Lonza) 
overnight. Monolayers of the cells were scratched with pipette tips and stimulated with 200 
ng/ml of VEGF-C. Cell images were obtained with the Biozero BZ-X700 microscope, and 
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wound closure was analyzed by NIH ImageJ software. 
For the transwell migration assay, hLECs starved as described above were seeded in the 
upper chamber of transwell migration chamber (8 µm pore size; Corning) at 2 × 104 cells per 
chamber. The lower chamber was filled with 200 ng/ml of VEGF-C/EBMTM-2 Basal Medium. 
At 12 hr after seeding, membrane filters were fixed with 4% PFA/PBS and stained with DAPI. 
hLECs migrated to the lower surface of the membrane filter were imaged using the Biozero 
BZ-X700 microscope, and the cell number was counted. 
For time-lapse analysis of wound-induced cell migration, hLECs transfected with 
siRNA for Arf6 were cultured on the µ-Dish dish (ibidi, Germany) to full confluency, and 
starved in serum-free EBMTM-2 Basal Medium overnight. The monolayer of the hLECs was 
scratched with pipette tips, and then incubated in the humidified chamber of a time-lapse 
microscopy (FLUOVIEW FV10i, Olympus) in the presence or absence of 200 ng/ml of 
VEGF-C at 5% CO2 and 37°C. Cell migration at the wounded area was recorded every 10 
min for 20 hr by tracking the nucleus using the manual-tracking tool of NIH ImageJ. Cell 
trajectories were analyzed using the Chemotaxis and Migration Tool Software (ibidi). 
Accumulated distance was calculated as the sum of all cell movement. Euclidean distance 
represents the straight distance between the start and end point of cell migration. 
Directionality was calculated by dividing euclidean distance by accumulated distance. 
 
Western Blotting 
Western blotting was carried out as previously reported [60], using anti-Arf6 that was 
previously generated by us [134], anti-β1 integrin TS2/16 (Santa Cruz) and anti-α-tubulin 
(Sigma-Aldrich) antibodies. 
 
Assay for the activated β1 integrin level and focal adhesion formation 
To evaluate the activated β1 integrin levels at the plasma membrane, control and 
Arf6-knocked-down hLECs were stimulated with VEGF-C. Cells were fixed with 4% 
PFA/PBS, blocked with the blocking buffer, then immunostained by sequential incubation 
with anti-active β1 integrin (9EG7, BD Biosciences) and Alexa Fluor®-488-conjugated 
secondary antibodies (Thermo Fisher Scientific). Immunofluorescence images were obtained 
with Biozero BZ-X700 microscope, and the fluorescence intensities for the activated β1 
integrin were analyzed by NIH ImageJ software. 
For focal adhesion formation assay, control and Arf6-knocked-down hLECs were 
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stimulated with VEGF-C for the indicated times. Cells were fixed, blocked, and stained with 
anti-paxillin (BD Biosciences) and Alexa Fluor®-488-conjugated secondary antibodies. 
Images were obtained by Leica TCS SP5 confocal microscope, and the focal adhesion 
formation was analyzed by ImageJ software. 
 
Internalization of β1 integrin 
Control and Arf6-knocked-down hLECs were incubated with anti-β1 integrin TS2/16 
antibody for 30 min on ice. The β1 integrin/antibody complex on the plasma membrane was 
allowed to be internalized by incubating with 200 ng/ml of VEGF-C at 37°C for the indicated 
time in the presence of 0.6 µM of primaquine, an inhibitor for the recycling of β1 integrin to 
the plasma membrane. Anti-β1 integrin antibody on the cell surface was removed by washing 
with the ice-cold stripping solution (0.5% acetic acid, 0.5 M NaCl and 0.05% BSA). The cells 
were fixed with 4% PFA/PBS, permeabilized with 0.1% Triton X-100/PBS, and visualized 
for the internalized β1 integrin with Fluor®-488-labeled secondary antibody. Z-stack 
fluorescence images were obtained with Leica TCS SP5 confocal microscope, and the 
fluorescence intensities of internalized β1 integrin were analyzed by NIH ImageJ software. 
 
Tumor lymphangiogenesis and tumor progression 
LEC-Arf6 cKO mice were administered with 3 mg of tamoxifen into peritoneal cavity once a 
day for 7 days and subcutaneously transplanted with B16 melanoma cells (2 × 106 cells) 
suspended in 100 µl of serum-free DMEM into the dorsal flank. From day 6 after the 
transplantation, tumor volumes were measured by digital caliper and calculated using the 
following formula: tumor volume = length × width2 × 0.52. After 14 days of the 
transplantation, tumors were dissected, fixed with 4% PFA/PBS and subjected to assay for 
tumor lymphangiogenesis. 
 
Statistical analysis 
Student’s t-test and ANOVA were used to calculate the statistical significance between two 
experimental groups and more than two experimental groups, respectively. The value of P < 
0.05 was considered as statistical significance. Each result was obtained from at least three 
independent experiments, and all quantitated data are represented as mean ± SEM.  
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4. Results 
Ablation of Arf6 from lymphatic endothelial cells causes edema and defect in lymphatic 
vascular network formation 
As we have previously reported [60], the re-examination of Arf6-/- embryos confirmed that 
knockout of Arf6 induces the dorsal skin edema in E13.5 and E15.5 embryos (Figure 10A). 
Because impairment in lymphatic vascular formation causes hydrops fetalis with back skin 
edema [126, 135-137], we examined the lymphatic vascular network formation in the back 
skin of Arf6-/- embryos by immunofluorescent staining for the specific marker of mouse LECs 
(mLECs) LYVE-1 (Figure 10B). As expected, Arf6-/- embryos showed the aberrant 
morphology of the lymphatic vascular network: extension of the front tip of lymphatic vessels 
toward the dorsal midline was delayed in Arf6-/- embryos. Detailed analysis revealed the fewer 
branch points, shorter total vessel length, and enlarged lymphatic vessels in Arf6-/- embryos 
(Figure 10C). In support of these observations, embryonic Prox1+ and LYVE-1+ mLECs 
isolated from dorsal skins of E16.5 embryos (Figure 11A) expressed the Arf6 protein and its 
mRNA (Figure 11B,C). In addition, Arf6 was expressed in the lymph sac of E13.5 embryos 
(Figure 11D). 
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Figure 10. Arf6-/- and LEC-Arf6 cKO mice induce dorsal skin edema and 
abnormal lymphatic vascular network 
(A, D) Appearance of Arf6-/- and LEC-Arf6 cKO embryos in comparison with that 
of control Arf6+/+ and Arf6flox/flox embryos, respectively. Note that the edema (white 
arrows) on the back of E13.5 and 15.5 Arf6-/- embryos and of E15.5 LEC-Arf6 cKO 
were induced. (B, E) Aberration of dorsal subcutaneous lymphatic vascular network 
in E15.5 Arf6-/- and LEC-Arf6 cKO embryos. Lymphatic vessels were 
immunostained for LYVE-1 (green). White dashed lines indicate the dorsal midline 
of the embryo. (C, F) Immunostained images of lymphatic vessels shown in (A) 
were quantified for branch number of lymphatic vessels/area (left panel), lymphatic 
vessel length/area (middle panel), and width of lymphatic vessels/area (right panel) 
in control Arf6+/+ and Arf6-/- embryos (C) and control Arf6flox/flox and LEC-Arf6 cKO 
embryos (F). Area of 2250 × 1700 µm on both sides of the midline was measured. 
Each point represents individual value: n = 10 for both embryos in the left panel 
and n = 5 for both embryos in the middle and right panels of (C), and n = 8 for 
Arf6flox/flox embryos and n = 13 for LEC-Arf6 cKO embryos in (F). Statistical 
significance was assessed using student’s t-test. *P < 0.05, **P < 0.01, ***P < 
0.005. Scale bar, 200 µm.  
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Figure 11. Arf6 is expressed in mLECs 
(A) Verification of mLECs and mVECs purified from E16.5 embryos by qRT-PCR 
for the lymphatic markers Prox1 and Lyve-1, and the blood vessel marker Flt1. (B) 
The expression levels of Arf6 protein in hLECs, HUVECs, mLECs, and mVECs 
determined by Western blotting. (C) Arf6 mRNA expression levels in hLECs and 
HUVECs analyzed by qRT-PCR. The data were shown as mean ± SEM from three 
independent experiments. Statistical significance was assessed using unpaired 
Student’s t-test. *P < 0.05. (D) Expression of Arf6 (red) in LYVE-1-positive 
transverse jugular lymph sacs (purple) of E13.5 mouse embryos. Scale bars, 200 
µm.  
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The defect of lymphangiogenesis observed in Arf6-/- embryos and the expression of 
Arf6 in mLECs led us to hypothesize that Arf6 in mLECs functions in development 
lymphangiogenesis. To test this hypothesis, we generated LEC-Arf6 cKO mice. Arf6 would 
be successfully deleted from mLECs in LEC-Arf6 cKO mice since the tdsRed signal was 
detected in the lymphatic vessels of R26GRR;Prox1-CreER;Arf6flox/+ mice treated with 
tamoxifen (Figure 12). Consistent with the results obtained with Arf6-/- mice, E15.5 LEC-Arf6 
cKO mice showed edema, delay of the lymphatic vessel extension, and defects in the branch 
points, vessel length and vessel width (Figure 10D-F). The phenotypes observed in Arf6-/- and 
LEC-Arf6 cKO embryos were not due to the defect in blood vessel formation as was shown in 
Figure 13. Although heart development disorder is known to cause embryonic edema, 
LEC-Arf6 cKO embryos did not show any heart defect in the histological analysis (Figure 14). 
Taken together, these results strongly suggest that Arf6 in mLECs is essential for the 
developmental lymphangiogenesis. 
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Figure 12. Cre recombinase expression in mLECs of the jugular lymph sac 
Transverse jugular sections prepared from E13.5 and E15.5 GFP-expressing control 
R26GRR;Arf6flox/+ and R26GRR;Prox1-CreERT2;Arf6flox/+ embryos, which were 
administrated with tamoxifen, were stained for LYVE-1 (cyan) and DAPI (blue). 
tdsRed signal (red) indicates the tamoxifen-stimulated Cre recombinase activity. 
JLS, jugular lymph sac. JV, jugular vein. Scale bars, 200 µm.  
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Figure 13. mLEC-specific Arf6 knockout does not impair the blood vessel 
formation. (A) Confocal z-stack images of dorsal view of subcutaneous blood 
vessels stained for PECAM-1 in E15.5 control Arf6flox/flox and LEC-Arf6-cKO 
embryos. (B) Quantification of branch points of blood vessels/area (393 × 393 µm) 
in control Arf6flox/flox (n = 3) and LEC-Arf6-cKO (n = 3) embryos. (C) 
Quantification of total blood vessel length/area (393 × 393 µm) in control Arf6flox/flox 
(n = 3) and LEC-Arf6-cKO (n = 3) embryos. The data shown were the mean ± SEM 
from at least three independent experiments. Statistical significance was assessed 
using Student’s t-test. NS, not significant. Scale bar, 50 µm.  
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Figure 14. LEC-Arf6 cKO mice do not show heart failure. (A) Schematic 
anatomy of the heart in E15.5 embryos. LA, left atrium. LV, left ventricle. RA, 
right atrium. RV, right ventricle. (B) Hematoxylin & Eosin staining of transverse 
heart sections of E15.5 control Arf6flox/flox and LEC-Arf6-cKO embryos. (C) 
Quantification of the thickness of left ventricle apex wall (LVA), right ventricle 
apex wall (RVA), left ventricle middle wall (LVM), right ventricle middle wall 
(RVM) and interventricular septum (IVS) in E15.5 control Arf6flox/flox and 
LEC-Arf6-cKO embryos. The data shown are mean ± SEM from at least three 
independent experiments. Statistical significance was assessed using Student’s 
t-test. NS, not significant. Scale bar, 200 µm.  
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Arf6 plays a role in the formation of lymph sacs 
To examine the functions of Arf6 in an early event of developmental lymphangiogenesis, we 
analyzed primary lymph sac formation. In E13.5 and E15.5 LEC-Arf6 cKO embryos, 
LYVE-1+ and PECAM-1+ lymph sacs were enlarged compared with those in control 
Arf6flox/flox embryos (Figure 15). 
 
 
Figure 15. Jugular lymph sacs enlarge in LEC-Arf6 cKO mice 
Transverse jugular sections of E13.5 and E15.5 control Arf6flox/flox and 
LEC-Arf6-cKO embryos were immunostained for LYVE-1 (red), PECAM-1 
(green) and DAPI (blue). Note that the LYVE-1 positive JLS in LEC-Arf6 cKO 
embryos enlarged compared with that in control embryos. JV, jugular vein. JLS, 
jugular lymph sac. Scale bar, 200 µm.  
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Sprouting of the lymphatic vessel from lymph sacs is the second step in the 
developmental lymphangiogenesis to form the lymphatic vascular network. Arf6 appeared to 
play a function in the sprouting of lymphatic vessels, since LEC-Arf6 cKO embryos lacked 
any sprouting tips and showed enlarged LYVE-1+ and Prox1+ lymphatic vessels (Figure 16A). 
The enlargement of lymphatic vessels was not due to the enhancement of mLEC proliferation 
as assessed by immunostaining of developing lymphatic vessels for the proliferation marker 
Ki67 (Figure 17B). This result was supported by the finding that knockdown of Arf6 in 
hLECs was without effects on hLEC proliferation in vitro (Figure 17). Moreover, it was found 
that the nuclei of mLECs in LEC-Arf6 cKO embryos were spherical, while those of control 
mLECs were oval (Figure 16C), suggesting that Arf6 regulates sprouting by controling the 
cell migration. These results demonstrate that Arf6 in mLECs plays an important role in 
sprouting from the lymph sac to form the lymphatic vascular network.  
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Figure 16. Arf6 regulates lymphatic vessel sprouting and tip cell morphology 
(A) Representative images of sprouting lymphatic vessels in E15.5 control 
Arf6flox/flox (n = 4) and LEC-Arf6 cKO (n = 3) (left panels). Transverse jugular 
sections were co-immunostained for LYVE-1 (red) and Prox1 (green). Arrowheads 
indicate sprouts of lymphatic vessels. Immunostained images shown in the left 
panels were quantified for the number of Prox1+ lymphatic tip cells in the distal 
migration front area of lymphatic vessels (right panel). Scale bar, 200 µm. (B) 
Representative images of proliferating mLECs in the subcutaneous lymphatic 
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vessel of E15.5 control Arf6flox/flox (n = 5) and LEC-Arf6 cKO (n = 5) embryos 
co-immunostained for Prox1 (green) and Ki67 (red) (left panels). Arrowheads 
represent Prox1+/Ki67+ proliferating mLECs (left panel). Percentages of 
Prox1+/Ki67+ proliferative mLECs of total Prox1+ mLECs in the distal migrating 
front area of lymphatic vessels were quantified (right panel). (C) Representative 
images of subcutaneous lymphatic vessels in E15.5 control Arf6flox/flox (n = 3) and 
LEC-Arf6-cKO embryos (n = 3) co-immunostained for LYVE-1 (red) and Prox1 
(green). Lower panels are magnified images of the square area in the upper panels. 
Arrowheads in the magnified images indicate the oval nucleus. Immunostained 
images were quantified for sphericity of nucleus (width/length) (right panel). 
Statistical significance was assessed using student’s t-test. NS, not significant, *P < 
0.05, ***P < 0.005. Scale bar, 200 µm (A, B) and 25 µm (C). 
 
 
Figure 17. Arf6 is not involved in cell proliferation of hLECs 
(A) Knockdown of Arf6 in hLECs. (B) Effect of Arf6 knockdown on the cell 
proliferation of hLECs. After two days of cell culture, cell number was counted. 
The data shown are mean ± SEM from five independent experiments. Statistical 
significance was assessed using One-way ANOVA. NS, not significant.  
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Arf6 in mLECs promotes in vitro capillary tube formation by regulating cell migration 
upon VEGF-C stimulation 
It has been reported that VEGF-C signaling regulates lymphatic vascular development [138]. 
To address a question whether Arf6 regulates VEGF-C-dependent lymphatic vascular 
formation, we investigated the involvement of Arf6 on the VEGF-C-dependent in vitro 
capillary tube formation by hLECs. As was expected, knockdown of Arf6 in hLECs (Figure 
17) impaired the VEGF-C-induced tube formation (Figure 18A). 
Since VEGF-C signaling regulates migration of LECs [138, 139], which is an essential 
cell event for lymphatic vascular development, we examined whether Arf6 regulates hLEC 
migration by wound healing and transwell migration assays. At 24 hr after wounding, the 
VEGF-C-dependent wound closure was significantly delayed in Arf6-knocked-down hLECs 
(~40% closure) compared with control (~75% closure) (Figure 18B). Transwell migration of 
hLECs using VEGF-C as a chemoattractant was also markedly inhibited by knockdown of 
Arf6 (Figure 18C). Thus, Arf6 appeared to play an important role in the cell migration.
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Figure 18. Arf6 regulates in vitro capillary tube formation and cell migration 
of hLECs 
(A) Representative images of in vitro capillary tube formation by control and 
Arf6-knocked-down hLECs (left panels), and quantified data for total tube length 
(right panel). The control and Arf6-knocked-down hLECs were stimulated without 
or with 200 ng/ml of VEGF-C for 24 hr. Total vessel length was calculated in 4 
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fields/experiments of three independent experiments. (B) Representative images of 
wound healing by control and Arf6-knocked-down hLECs (left panels), and 
quantified data for percentages of wound closure (right panel). Confluent 
monolayers of hLECs transfected with control and Arf6 siRNAs were scratched and 
immediately treated without or with 200 ng/ml of VEGF-C, and images were 
obtained at 0 and 24 hr after wounding. Dotted lines in the images indicate the 
border of the wound. Wound closure was measured in 4 fields/experiment of four 
independent experiments and represented as percentages of wound distance during 
24 hr. (C) Cell migration of control and Arf6-knocked-down hLECs stimulated 
without or with 200 ng/ml of VEGF-C. Cells migrated to the lower surface of the 
membrane filter in transwell migration chamber were stained with DAPI. 
DAPI-positive cells in four fields per sample were counted, and the data were 
shown as means ± SEM from at least 3 independent experiments. Statistical 
significance was assessed using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 
0.005. Scale bar, 200 µm. 
 
 
Arf6 regulates directional cell migration of LECs 
To further investigate whether Arf6 regulates the directional cell migration, time-lapse 
tracking of hLEC movement in response to VEGF-C stimulation was analyzed (Figure 19A). 
Although knockdown of Arf6 did not affect accumulated distance, euclidean distance and 
directionality of cells were significantly reduced by Arf6 knockdown (Figure 19B). Thus, 
Arf6 is required for the directional cell migration but not for unsophisticated cell movement. 
Interference with the directed cell migration by Arf6 knockdown may be resulted from 
the disturbance of cell polarity, since Golgi orientation, which has been shown to be involved 
in the cell polarity [136, 137, 140], was randomized in Arf6-knocked-down hLECs (Figure 
19C): although migrating control cells at the wounded site elongated (left top panel, arrow 
heads), Arf6-knocked-down cells remained spherical (middle and right top panels), which is 
consistent with the results shown in Figure 16C that the nuclei of mLECs in LEC-Arf6 cKO 
embryos showed spherical shape while those of control mLECs was oval. Taken together, 
these results suggest that Arf6 in LECs regulates directional cell migration by controlling cell 
polarity.  
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Figure 19. Arf6 knockdown causes defect in directed cell migration of hLECs. 
(A) Tracking of cell migration during wound healing by time-lapse video 
microscopy. Control and Arf6-knocked-down hLECs were grown to the confluence, 
scratched, and stimulated with 200 ng/ml of VEGF-C. Images were obtained every 
10 min for 20 hr after wounding. Each line represents the trajectory of an individual 
cell. Red and black lines indicate the euclidean distance over and less than 100 µm, 
respectively. Dotted lines indicate the boarder of the wound. Each experiment was 
performed four times, and at least 60 cells per experiment were analyzed. (B) 
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Images shown in (A) were quantified for accumulated distance (left panel), 
euclidean distance (middle panel), and directionality (right panel), which was 
calculated by dividing euclidean distance by accumulated distance. (C) 
Representative phase contrast microscopic images of control and 
Arf6-knocked-down of hLECs (upper images) and immunostained images with 
anti-GM130 antibody (green), phalloidin (red), and DAPI (blue) (lower images) at 
the wounded edge (left panels). Arrowheads indicate elongated cells. Arrows 
indicate the migrating direction of the cell as decided by the location of Golgi. 
Images were quantified for cells with polarized Golgi (right panel). At least 200 
cells per experiment were analyzed, and data were shown as means ± SEM from at 
least 3 independent experiments. Statistical significance was assessed using 
one-way ANOVA. NS, not significant, *P < 0.05, **P < 0.01. Scale bar, 25 µm.  
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Arf6 regulates internalization of β1 integrin in LECs 
Impairment of the internalization of cell surfact β1 integrin in nascent endothelium disrupts 
arterial endothelial cell polarity and lumen formation [141-143]. In addition, it has been 
reported that Arf6 signaling regulates the internalization of β1 integrin [144, 145]. These 
reports led us to examine whether Arf6 is involved in the β1 integrin internalization in LECs. 
The total amount of β1 integrin in hLECs was not affected by knockdown of Arf6 (Figure 
20A). When the levels of active form of surface β1 integrin and the adhesion molecule 
paxillin were analyzed, levels of both molecules were significantly increased in 
Arf6-knocked-down hLECs (Figure 20B). In addition, β1 integrin internalization promoted by 
VEGF-C stimulation of hLECs in a time-dependent manner was almost completely inhibited 
by knockdown of Arf6 (Figure 20C). These results, taken together, suggest that Arf6 regulates 
VEGF-C-induced cell polarity and directional cell migration by controling β1 integrin 
internalization in LECs.  
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Figure 20. Arf6 regulates β1 integrin internalization in hLECs. (A) Western 
blots of β1 integrin levels in control and Arf6-knocked-down hLECs (left panel), 
and their quantified data (right panel). (B) Representative images of surface 
activated β1 integrin (green, upper panels) and paxillin (white, lower panels) in 
control and Arf6-knocked-down hLECs (left panels), and quantified data for their 
levels (right panels). (C) Representative images of time-dependent β1 integrin 
internalization (left panels) and its quantified data (right panel). The internalized β1 
integrin was shown in green. Data were shown as means ± SEM from at least 3 
independent experiments. Statistical significance was assessed using One-way 
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ANOVA. NS, not significant, * P < 0.05, **P < 0.01. Scale bar, 25 µm (B) and 50 
µm (C).  
 
 
Ablation of Arf6 from LECs interferes with tumor lymphangiogenesis and cancer 
progression 
Cancer progression and lymphatic metastasis are tightly related with tumor 
lymphangiogenesis [146, 147]. These reports and the results shown above raised a possibility 
that Arf6 in LECs is involved in tumor lymphangiogenesis and cancer progression. To 
address these issues, B16 melanoma cells were transplanted into tamoxifen-treated LEC-Arf6 
cKO mice (Figure 21A). The tumor volume produced was significantly reduced by knockout 
of Arf6 in mLECs (Figure 21B,C). Correlated to this result, tumor lymphangiogenesis was 
suppressed by Arf6 knockout (Figure 22). Thus, Arf6 in mLECs plays an important role in 
tumor lymphangiogenesis, thereby regulating cancer progression. These results provide a new 
cancer therapeutic opportunity. 
 
 
Figure 21. The effect of Arf6 ablation from LECs on tumor progression 
Scheme of the assay for the effect of Arf6 ablation from mLECs on tumor 
progression. Tamoxifen (3 mg) was daily injected into the peritoneal cavity of the 
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mice for one week, and B16 melanoma cells (2 × 104 cells) were subcutaneously 
transplanted into the right lower back region of the mice. The size of the tumor was 
measured by digital caliper every two days from day 6 after the transplantation. (B) 
Tumor volumes produced in vehicle-treated Arf6flox/flox, tamoxifen-treated Arf6flox/flox, 
and tamoxifen-treated LEC-Arf6 cKO mice were measured according to the 
schedule described in (A). (C) At 14 days of the transplantation, tumors were 
dissected, and 3 examples were shown. The data shown in (B) are mean ± SEM 
from three independent experiments. Statistical significance was assessed using 
One-way ANOVA. NS, not significant. **P < 0.01. 
 
 
 
Figure 22. Arf6 in mLECs positively regulates tumor lymphangiogenesis. 
Representative images of lymphatic vessels in B16 melanoma tumors produced in 
control Arf6flox/flox (n = 3) and LEC-Arf6 cKO mice (n = 3). Tumor sections were 
co-immunostained for LYVE-1 (red) and PECAM1 (green) (upper panels). Arrows 
and the letter T indicate the lymphatic vessel and the tumor, respectively. White 
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dashed lines are the border between the tumor and dermis. Quantification of 
percentages of lymphatic vessels/area (1525 × 1140 µm area) (lower panel) was 
calculated in 10 fields of images/experiments. Data shown were the mean ± SEM 
from at least 3 independent experiments. Statistical significance was assessed using 
student’s t-test, *P < 0.05. Scale bar, 200 µm.  
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Discussion 
The results obtained in this study demonsrate for the first time that the small G protein Arf6 in 
LECs plays an important role in the VEGF-C-induced directional cell migration, which is 
critical for lymphatic vascular network formation, by regulating β1 integrin internalization, 
providing insight into the molecular mechanism of developmental lymphangiogenesis. 
Furthermore, we clarified that Arf6 in LECs plays pivotal roles in tumor lymphangiogenesis 
and cancer progression, giving a new cancer therapeutic opportunity. Thus, our findings in 
this study provide insight into not only physiological but also pathological functions of Arf6 
in LECs. 
Although Arf6 has been well established to regulate the integrin recycling [58, 144, 
148], the molecular mechanisms for VEGF-C-dependent Arf6-mediated β1 integrin recycling 
in LECs still remained unclear. Activation of Arf6 in LECs in response to VEGF-C 
stimulation could be essential for the integrin recycling. This assumption is supported by the 
report that the Arf6-specific GEF GEP100 promotes the β1 integrin endocytosis to enhance 
the cell attachment to and spreading on the β1 integrin substrate fibronectin [144]. Recently, 
we have reported that Arf6 is activated by the GTPase dynamin2, which promotes scission of 
the invaginated plasma membrane in a manner dependent on its conformational change 
induced upon GTP hydrolysis [149]. The Arf6 activation by dynamin2 is mediated by the 
Arf6-specific GEFs such as EFA6A, EFA6B, and EFA6D during clathrin-mediated 
endocytosis [149]. If it is the case that these Arf6 GEFs are involved in VEGF-C-stimulated 
Arf6 activation in LECs, dynamin2 mediates VEGF-C-dependent Arf6 activation through an 
Arf6 GEF(s). This issue remains to be clarified. 
What is the cellular signaling downstream of the activated Arf6 coupling to the β1 
integrin endocytosis in VEGF-C-stimiulated LECs? It is plausible that the lipid kinase PIP5K, 
which is directly activated by the active form of Arf6 to produce the versatile signaling lipid 
PI(4,5)P2 at the plasma membrane [21], is involved in this cellular signaling as an effector 
molecule of Arf6 activated by VEGF-C stimulateion. The PIP5K product PI(4,5)P2 regulates 
activities of actin-binding proteins such as the actin severing and capping protein gelsolin, 
thereby reorganizing actin cytoskeleton to facilitate endocytosis of membrane proteins 
[150-152]. Alternatively, PLD1 which produces the signaling lipid PA may function as a 
mediator for the active form of Arf6 coupling to β1 integrin endocytosis. This idea is derived 
from the reports that PLD1 is directly activated by Arf6 in response to agonist stimulation 
[153, 154], and its product PA facilitates endocytosis by forming the membrane curvature at 
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the neck of the deeply invaginated membrane [155, 156]. In addition to these possible 
functions of PIP5K and PLD1 in β1 integrin endocytosis, these two lipid-metabolizing 
enzymes mutually accelerate their activation by a positive feedback mechanism: PA is 
necessary for the activation of PIP5K by Arf6 [156], and PI(4,5)P2 supports PLD1 activation 
by Arf6 [157]. 
Besides Arf6, other proteins may be involved in VEGF-C-stimulated β1 integrin 
endocytosis to regulate directional cell migration. For example, the endocytic adaptor protein 
Numb has been reported to bind β1 integrin and control integrin endocytosis for directional 
cell migration with aPKC and PAR-3 [158]. Thus, the molecular mechanism of β1 integrin 
endocytosis seems to be very complicated, and it is of interest to clarify the precise molecular 
mechanism for VEGF-C-dependent β1 integrin endocytosis, especially crosstalk of cellular 
signaling pathways in this cell event. 
Interestingly, it has been reported that in a model mouse of  
hypotrichosis-lymphedema-telangiectasia, Ragged Opossum, the Arf6 GAP ARAP3 in 
lymphatic vessels that is necessary for lymphatic vascular development is down-regulated 
[159]. Furthermore, this report demonstrated that Arap3-/- embryos show the lymphatic 
vascular network deficiency with enlarged lymphatic vessels, which are the same phenotypes 
observed in Arf6-/- and LEC-Arf6 cKO mice (Figure 10). These observations indicate that 
appropriate cycling of Arf6 between activation and inactivation that are precisely regulated by 
Arf6-specific GEFs and GAPs, respectively, is essential for the development of dermal 
lymphatic vasculature network. This idea is consistent with our recent report demonstrating 
that cycling between active and inactive states of Arf6 is required for promoting neurite 
outgrowth [160]. 
The edema on the back of Arf6-/- mice was observed at E13.5 (Figure 10A), while 
LEC-Arf6 cKO embryos showed the edema at E15.5 but not at E13.5 (Figure 10D). This 
difference in the embryonic days inducing edema between these two types of Arf6-deficient 
mice would be attributable to the involvement of another type(s) of cells distinct from LECs 
in an earlier step of lymphangiogenesis. This idea is supported by the report that the 
lymphatic vascular system predominantly originates from the vein at earlier stage of 
development (E7.5) before lymphatic vessels are formed at E9.5 in mouse embryos [161]. 
Moreover, it has been reported that non-venous mesenchymal cells also contribute to an 
earlier step(s) of lymphatic development as a source of LECs [162]. These observations 
explain well why we did not observe any defects in the lymphatic vessel formation in the 
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VEC-specific Arf6 cKO mice (data not shown), which had been generated previously [60], 
and why the edema was induced in Arf6-/- embryos earlier than in LEC-Arf6 cKO embryos: 
ablation of Arf6 from both venous and non-venous mesenchymal cells in Arf6-/- embryos 
might induce the lymphedema earlier than LEC-Arf6-cKO. 
Finally, we demonstrated in this study that Arf6 in LECs is a key molecule for tumor 
lymphangiogenesis and cancer progression (Figure 21 and Figure 22). Tumor 
lymphangiogenesis, as well as tumor angiogenesis, is a potential therapeutic target for cancer 
treatment [153, 154]. We have recently reported that Arf6 expressed in VECs plays an 
important role in tumor angiogenesis and cancer progression: ablation of Arf6 from mVECs 
inhibits tumor angiogenesis, therefore suppressing tumor growth [60]. Thus, Arf6 in 
pan-endothelial cells is a highly potential therapeutic target to prevent cancer progression. 
However, recent preclinical studies have suggested that anti-angiogenic therapy promotes 
cancer metastasis by inducing hypoxia in cancer cells [163, 164]. It is noteworthy that Arf6 
expressed in breast cancer cells is required for cancer metastasis [34]. Thus, Arf6 plays 
critical roles in tumor lymphangiogenesis/angiogenesis and cancer metastasis. These reports 
and our results obtained in this study suggest that an inhibitor(s) of Arf6 could efficiently 
prevent both tumor progression and metastasis. Specific inhibitors of Arf6 might provide a 
new cancer therapeutic opportunity.  
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